About AbbVie (NYSE:ABBV)
AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).
Industry, Sector and Symbol
Industry Specialty & Advanced Pharmaceuticals
Trailing P/E Ratio35.6242424242424
Forward P/E Ratio15.74
Sales & Book Value
Annual Sales$28.22 billion
Price / Sales6.62
Cash Flow$5.58 per share
Price / Cash21.08
Book Value$2.85 per share
Price / Book41.25
Net Income$5.31 billion
Return on Equity152.78%
Return on Assets13.42%
AbbVie (NYSE:ABBV) Frequently Asked Questions
What is AbbVie's stock symbol?
AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."
How often does AbbVie pay dividends? What is the dividend yield for AbbVie?
AbbVie announced a quarterly dividend on Thursday, February 15th. Stockholders of record on Friday, April 13th will be given a dividend of $0.96 per share on Tuesday, May 15th. This represents a $3.84 annualized dividend and a dividend yield of 3.27%. The ex-dividend date is Thursday, April 12th. This is an increase from AbbVie's previous quarterly dividend of $0.71. View AbbVie's Dividend History.
How will AbbVie's stock buyback program work?
AbbVie announced that its board has approved a share buyback plan on Friday, February 16th 2018, which permits the company to buyback $10,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to purchase shares of its stock through open market purchases. Stock buyback plans are often an indication that the company's management believes its shares are undervalued.
How were AbbVie's earnings last quarter?
AbbVie Inc (NYSE:ABBV) posted its earnings results on Friday, January, 26th. The company reported $1.48 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.44 by $0.04. The firm had revenue of $7.74 billion for the quarter, compared to the consensus estimate of $7.53 billion. AbbVie had a return on equity of 152.78% and a net margin of 18.82%. AbbVie's quarterly revenue was up 13.9% compared to the same quarter last year. During the same period last year, the company earned $1.20 EPS. View AbbVie's Earnings History.
When will AbbVie make its next earnings announcement?
What guidance has AbbVie issued on next quarter's earnings?
AbbVie issued an update on its first quarter earnings guidance on Friday, January, 26th. The company provided earnings per share guidance of $1.77-1.79 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.49. AbbVie also updated its FY18 guidance to $7.33-7.43 EPS.
Where is AbbVie's stock going? Where will AbbVie's stock price be in 2018?
14 Wall Street analysts have issued twelve-month price targets for AbbVie's stock. Their forecasts range from $88.00 to $157.00. On average, they expect AbbVie's stock price to reach $121.15 in the next twelve months. View Analyst Ratings for AbbVie.
What are Wall Street analysts saying about AbbVie stock?
Here are some recent quotes from research analysts about AbbVie stock:
- 1. BMO Capital Markets analysts commented, "On its fiscal 3Q18 earnings call, MDT said it does not expect the first-in- human use of its surgical robot in the next couple of months as the company had intended. Recall, MDT had previously said that it expected to be in clinical use by end of its fiscal 2018." (2/15/2018)
- 2. According to Zacks Investment Research, "AbbVie’s key drug Humira has been performing well based on strong demand trends for the drug, despite new competition. Moreover, Imbruvica has multibillion dollar potential and AbbVie is exploring the possibility of label expansion into solid tumors and autoimmune diseases. AbbVie’s shares outperformed the industry in the past one year supported by a series of positive news including promising data from several pivotal studies, regulatory approvals in the U.S., Europe, and Japan for its competitive HCV medicine Mavyret and FDA approval for the sixth indication for Imbrivica and settlement of its Humira patent disputes with Amgen. Also, several pivotal data readouts and regulatory milestones are expected in 2018. However, HCV sales continue to be hurt by intensifying competition. Estimates have gone up slightly ahead of the Q4 earnings release. AbbVie has a positive record of earnings surprises in the recent quarters." (1/22/2018)
- 3. UBS Group AG analysts commented, "For other pipeline products, we already included appropriate risk-adj estimates and in some cases significant risk adj sales (Rova-T)," (9/25/2017)
Who are some of AbbVie's key competitors?
Some companies that are related to AbbVie include Salix Pharmaceuticals (SLXP), ConvaTec Group (CTEC), Advanced Accelerator Application (AAAP), Indivior (INDV), Supernus Pharmaceuticals (SUPN), Aimmune Therapeutics (AIMT), Repligen (RGEN), Mallinckrodt (MNK), TherapeuticsMD (TXMD), Assembly Biosciences (ASMB), Eagle Pharmaceuticals (EGRX), Rockwell Medical (RMTI), Novan (NOVN), CorMedix (CRMD), Macrocure (MCUR), DARA Biosciences (DARA), Check Cap (CHEK) and Omthera Pharmaceuticals (OMTH).
Who are AbbVie's key executives?
AbbVie's management team includes the folowing people:
- Richard A. Gonzalez, Chairman of the Board, Chief Executive Officer (Age 63)
- William J. Chase, Executive Vice President, Chief Financial Officer (Age 49)
- Michael Severino M.D., Executive Vice President - Research & Development, Chief Scientific Officer (Age 51)
- Laura J. Schumacher, Executive Vice President, External Affairs, General Counsel and Corporate Secretary (Age 53)
- Carlos Alban, Executive Vice President - Commercial Operations (Age 54)
- Henry O. Gosebruch, Executive Vice President, Chief Strategy Officer (Age 44)
- Timothy J. Richmond, Senior Vice President - Human Resources (Age 50)
- Azita Saleki-Gerhardt Ph.D., Senior Vice President - Operations (Age 53)
- Robert A. Michael, Vice President, Controller (Age 46)
- Robert J. Alpern M.D., Independent Director (Age 66)
Who owns AbbVie stock?
AbbVie's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.35%), Bank of New York Mellon Corp (1.05%), Geode Capital Management LLC (1.00%), Orbis Allan Gray Ltd (0.79%), Jennison Associates LLC (0.71%) and TIAA CREF Investment Management LLC (0.65%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Carlos Alban, Edward J Rapp, Henry O Gosebruch, Laura J Schumacher, Michael Severino, Richard A Gonzalez, Robert A Michael, Thomas A Hurwich, Timothy J Richmond and William J Chase. View Institutional Ownership Trends for AbbVie.
Who sold AbbVie stock? Who is selling AbbVie stock?
AbbVie's stock was sold by a variety of institutional investors in the last quarter, including American International Group Inc., Credit Agricole S A, Aristotle Capital Management LLC, Arrowstreet Capital Limited Partnership, Orbis Allan Gray Ltd, Alps Advisors Inc., LSV Asset Management and Metropolitan Life Insurance Co. NY. Company insiders that have sold AbbVie company stock in the last year include Azita Saleki-Gerhardt, Carlos Alban, Henry O Gosebruch, Laura J Schumacher, Michael Severino, Richard A Gonzalez, Robert A Michael, Timothy J Richmond and William J Chase. View Insider Buying and Selling for AbbVie.
Who bought AbbVie stock? Who is buying AbbVie stock?
AbbVie's stock was purchased by a variety of institutional investors in the last quarter, including Jennison Associates LLC, BlackRock Inc., Amundi Pioneer Asset Management Inc., Swedbank, SG Americas Securities LLC, Fred Alger Management Inc., Geode Capital Management LLC and Standard Life Aberdeen plc. View Insider Buying and Selling for AbbVie.
How do I buy AbbVie stock?
Shares of AbbVie can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AbbVie's stock price today?
One share of AbbVie stock can currently be purchased for approximately $117.56.
How big of a company is AbbVie?
AbbVie has a market capitalization of $187.68 billion and generates $28.22 billion in revenue each year. The company earns $5.31 billion in net income (profit) each year or $3.30 on an earnings per share basis. AbbVie employs 30,000 workers across the globe.
How can I contact AbbVie?
AbbVie's mailing address is 1 N Waukegan Rd, NORTH CHICAGO, IL 60064-1802, United States. The company can be reached via phone at +1-847-9327900.
MarketBeat Community Rating for AbbVie (ABBV)MarketBeat's community ratings are surveys of what our community members think about AbbVie and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
AbbVie (NYSE:ABBV) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Hold||Buy||Buy||Buy|
|Consensus Rating Score: ||2.43||2.64||2.63||2.57|
|Ratings Breakdown: ||1 Sell Rating(s)|
6 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
5 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
6 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
7 Hold Rating(s)
6 Buy Rating(s)
1 Strong Buy Rating(s)
|Consensus Price Target: ||$121.15||$100.46||$95.60||$76.31|
|Price Target Upside: ||2.75% upside||5.66% downside||1.11% upside||8.36% upside|
AbbVie (NYSE:ABBV) Consensus Price Target History
AbbVie (NYSE:ABBV) Analyst Ratings History
(Data available from 2/22/2016 forward)
AbbVie (NYSE:ABBV) Earnings History and Estimates Chart
AbbVie (NYSE ABBV) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|1/26/2018||Q4 2017||$1.44||$1.48||$7.53 billion||$7.74 billion||View||Listen|
|10/27/2017||Q3 2017||$1.39||$1.41||$7.00 billion||$7.00 billion||View||N/A|
|7/28/2017||Q2 2017||$1.40||$1.42||$6.93 billion||$6.94 billion||View||N/A|
|4/27/2017||Q1 2017||$1.26||$1.28||$6.49 billion||$6.54 billion||View||N/A|
|1/27/2017||Q416||$1.20||$1.20||$6.92 billion||$6.78 billion||View||Listen|
|10/28/2016||Q316||$1.21||$1.21||$6.55 billion||$6.43 billion||View||Listen|
|7/29/2016||Q216||$1.20||$1.26||$6.20 billion||$6.43 billion||View||Listen|
|4/28/2016||Q116||$1.14||$1.15||$6.03 billion||$5.96 billion||View||Listen|
|1/29/2016||Q415||$1.12||$1.13||$6.41 billion||$6.36 billion||View||Listen|
|10/30/2015||Q315||$1.08||$1.13||$5.90 billion||$4.94 billion||View||Listen|
|7/24/2015||Q215||$1.06||$1.08||$5.60 billion||$5.48 billion||View||Listen|
|4/23/2015||Q115||$0.85||$0.94||$718.50 million||$5.04 billion||View||Listen|
|1/30/2015||Q414||$0.86||$0.89||$5.34 billion||$5.45 billion||View||Listen|
|10/31/2014||Q3||$0.77||$0.89||$4.82 million||$5.02 million||View||Listen|
|7/25/2014||Q214||$0.76||$0.82||$4.70 billion||$4.93 billion||View||Listen|
|4/25/2014||Q114||$0.68||$0.71||$4.33 billion||$4.56 billion||View||Listen|
|1/31/2014||Q413||$0.82||$0.82||$5.10 billion||$5.11 billion||View||Listen|
|10/25/2013||Q313||$0.78||$0.82||$4.52 billion||$4.66 billion||View||Listen|
|7/26/2013||Q2 2013||$0.79||$0.92||$4.54 billion||$4.69 billion||View||Listen|
|4/26/2013||Q1 2013||$0.67||$0.68||$4.17 billion||$4.33 billion||View||Listen|
AbbVie (NYSE:ABBV) Earnings Estimates
2018 EPS Consensus Estimate: $7.58
2019 EPS Consensus Estimate: $8.42
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
AbbVie (NYSE:ABBV) Dividend Information
|Dividend Growth:||15.50% (3 Year Average)|
|Payout Ratio:||86.06% (Trailing 12 Months of Earnings) |
38.02% (Based on This Year's Estimates)
33.02% (Based on Next Year's Estimates)
|Track Record:||45 Years of Consecutive Dividend Growth|
AbbVie (NYSE:ABBV) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
AbbVie (NYSE ABBV) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 0.23%
Institutional Ownership Percentage: 69.49%
AbbVie (NYSE ABBV) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|2/20/2018||Robert A Michael||VP||Sell||992||$120.31||$119,347.52|| |
|12/18/2017||Timothy J Richmond||SVP||Sell||87,040||$98.45||$8,569,088.00||113,118|| |
|12/15/2017||Laura J Schumacher||Insider||Sell||145,510||$96.71||$14,072,272.10|| |
|11/21/2017||Richard A Gonzalez||Chairman||Sell||218,193||$94.01||$20,512,323.93||492,030|| |
|11/10/2017||Michael Severino||EVP||Sell||25,633||$94.69||$2,427,188.77||114,922|| |
|10/30/2017||Henry O Gosebruch||Insider||Sell||18,300||$90.55||$1,657,065.00||81,287|| |
|9/28/2017||Robert A Michael||VP||Sell||6,699||$88.00||$589,512.00||10,007|| |
|9/11/2017||Azita Saleki-Gerhardt||SVP||Sell||8,300||$85.02||$705,666.00||93,099|| |
|8/7/2017||Richard A Gonzalez||Chairman||Sell||193,131||$71.00||$13,712,301.00||469,623|| |
|8/4/2017||Richard A Gonzalez||Chairman||Sell||87,899||$71.02||$6,242,586.98||342,353|| |
|8/3/2017||Richard A Gonzalez||CEO||Sell||65,861||$71.00||$4,676,131.00||342,353|| |
|7/31/2017||Edward J Rapp||Director||Buy||4,000||$70.45||$281,800.00||15,498|| |
|7/31/2017||Henry O Gosebruch||Insider||Sell||18,000||$70.09||$1,261,620.00||96,074|| |
|6/14/2017||Carlos Alban||EVP||Sell||45,800||$70.00||$3,206,000.00||160,545|| |
|6/14/2017||Laura J Schumacher||Insider||Sell||79,800||$70.00||$5,586,000.00||187,625|| |
|5/19/2017||Richard A Gonzalez||Chairman||Sell||71,235||$65.49||$4,665,180.15||349,462|| |
|5/18/2017||William J Chase||CFO||Sell||38,300||$65.35||$2,502,905.00||209,043|| |
|5/4/2017||Carlos Alban||EVP||Sell||43,000||$67.00||$2,881,000.00||114,745|| |
|3/10/2017||Laura J Schumacher||Insider||Sell||40,000||$65.26||$2,610,400.00||147,415|| |
|3/10/2017||Robert A Michael||VP||Sell||5,132||$65.29||$335,068.28||16,706|| |
|3/10/2017||Timothy J Richmond||SVP||Sell||22,451||$65.29||$1,465,825.79||26,078|| |
|3/8/2017||Richard A Gonzalez||Chairman||Sell||72,016||$64.25||$4,627,028.00||369,113|| |
|12/2/2016||William J Chase||CFO||Sell||6,600||$59.19||$390,654.00||178,970|| |
|9/7/2016||Laura J Schumacher||Insider||Sell||50,000||$65.00||$3,250,000.00||144,138|| |
|6/24/2016||Laura J Schumacher||EVP||Sell||186,106||$60.03||$11,171,943.18||260,438|| |
|6/2/2016||Richard A Gonzalez||CEO||Sell||285,953||$63.82||$18,249,520.46||624,374|| |
|5/11/2016||Richard A Gonzalez||CEO||Sell||39,000||$63.80||$2,488,200.00||338,421|| |
|5/10/2016||Carlos Alban||EVP||Sell||47,438||$63.52||$3,013,261.76||149,444|| |
|5/10/2016||Thomas A Hurwich||VP||Sell||6,000||$63.59||$381,540.00||68,204|| |
|5/10/2016||Timothy J Richmond||SVP||Sell||21,583||$63.52||$1,370,952.16||44,615|| |
|3/8/2016||Laura J Schumacher||EVP||Sell||25,000||$56.09||$1,402,250.00||199,238|| |
|3/1/2016||Timothy J Richmond||SVP||Sell||12,866||$55.05||$708,273.30||79,064|| |
|4/28/2015||Richard A Gonzalez||CEO||Sell||102,964||$64.67||$6,658,681.88|| |
|3/2/2015||Laura J Schumacher||EVP||Sell||25,000||$60.30||$1,507,500.00|| |
|3/2/2015||Timothy J Richmond||SVP||Sell||14,388||$60.33||$868,028.04|| |
|12/22/2014||William J Chase||CFO||Sell||8,495||$68.00||$577,660.00|| |
|3/4/2014||Richard Gonzalez||CEO||Sell||4,799||$51.20||$245,708.80||395,403|| |
|3/3/2014||Azita Saleki-Gerhardt||SVP||Sell||2,443||$50.25||$122,760.75||85,828|| |
|3/3/2014||Carlos Alban||EVP||Sell||2,882||$50.09||$144,359.38||205,138|| |
|3/3/2014||William Chase||CFO||Sell||3,948||$50.22||$198,268.56||180,068|| |
|9/17/2013||Azita Saleki-Gerhardt||SVP||Sell||10,473||$45.84||$480,082.32||66,703|| |
|8/19/2013||Azita Saleki-Gerhardt||SVP||Sell||1,270||$43.01||$54,622.70||64,279|| |
|8/12/2013||Azita Saleki-Gerhardt||SVP||Sell||8,851||$44.91||$397,498.41||64,237|| |
|3/11/2013||Edward J Rapp||Director||Buy||2,500||$37.67||$94,175.00|| |
|2/4/2013||Frederick H Waddell||Director||Buy||2,000||$37.05||$74,100.00|| |
AbbVie (NYSE ABBV) News Headlines
AbbVie (NYSE:ABBV) SEC Filings
This page is loading this company's SEC Filings. Please wait...
AbbVie (NYSE:ABBV) Income Statement, Balance Sheet and Cash Flow Statement
AbbVie (NYSE ABBV) Stock Chart for Thursday, February, 22, 2018